Tags

Type your tag names separated by a space and hit enter

[Botulinum toxin for the treatment of major depressive disorder].
Fortschr Neurol Psychiatr 2014; 82(2):93-9FN

Abstract

OBJECTIVE

Botulinum toxin (BTX) plays an important role in the treatment and prophylaxis of migraine and is also used for the treatment of focal dystonia, spasm, hypersalivation, and hyperhydrosis. Recent clinical trials suggest that BTX treatment of muscles involved in the development of negative emotions may also have an antidepressant effect. This article gives a systematic review of the literature regarding BTX in the treatment of major depression.

METHODS

We screened the databases of Medline and Scopus using the search terms [("botulinum toxin" OR "botox") AND ("antidepressant" OR "depression" OR "depressed")]. The website www.clinicaltrials.gov was screened with the same search terms in order to detect current studies.

RESULTS

As of April 2013, we identified 3 studies that evaluated the antidepressant effects of BTX in the treatment of major depression. An improvement in mood after treatment with BTX was seen in a case series of 10 depressed patients. In a randomised, placebo-controlled study of thirty patients assigned to a verum (BTX, n = 15) or placebo (saline, n = 15) group, treatment with BTX has also shown a positive effect on mood. Another prospective, open-label study evaluated the antidepressive effect of BTX in 25 subjects with major depression. On www.clinicaltrials.gov we identified 2 ongoing studies, which are currently investigating the antidepressant effect of BTX.

CONCLUSION

Recently published studies have shown a reduction of depressive symptoms after treatment of the glabellar frown lines with BTX injections. Further clinical studies in larger patient samples are necessary to prove the efficacy and safety of BTX injections used for the treatment of depressive disorders.

Authors+Show Affiliations

Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm.Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm.Klinik für Neurologie, Universitätsklinikum Ulm.Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm.Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

ger

PubMed ID

24519192

Citation

Hawlik, A E., et al. "[Botulinum Toxin for the Treatment of Major Depressive Disorder]." Fortschritte Der Neurologie-Psychiatrie, vol. 82, no. 2, 2014, pp. 93-9.
Hawlik AE, Freudenmann RW, Pinkhardt EH, et al. [Botulinum toxin for the treatment of major depressive disorder]. Fortschr Neurol Psychiatr. 2014;82(2):93-9.
Hawlik, A. E., Freudenmann, R. W., Pinkhardt, E. H., Schönfeldt-Lecuona, C. J., & Gahr, M. (2014). [Botulinum toxin for the treatment of major depressive disorder]. Fortschritte Der Neurologie-Psychiatrie, 82(2), pp. 93-9. doi:10.1055/s-0033-1356093.
Hawlik AE, et al. [Botulinum Toxin for the Treatment of Major Depressive Disorder]. Fortschr Neurol Psychiatr. 2014;82(2):93-9. PubMed PMID: 24519192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Botulinum toxin for the treatment of major depressive disorder]. AU - Hawlik,A E, AU - Freudenmann,R W, AU - Pinkhardt,E H, AU - Schönfeldt-Lecuona,C J, AU - Gahr,M, Y1 - 2014/02/11/ PY - 2014/2/13/entrez PY - 2014/2/13/pubmed PY - 2014/10/7/medline SP - 93 EP - 9 JF - Fortschritte der Neurologie-Psychiatrie JO - Fortschr Neurol Psychiatr VL - 82 IS - 2 N2 - OBJECTIVE: Botulinum toxin (BTX) plays an important role in the treatment and prophylaxis of migraine and is also used for the treatment of focal dystonia, spasm, hypersalivation, and hyperhydrosis. Recent clinical trials suggest that BTX treatment of muscles involved in the development of negative emotions may also have an antidepressant effect. This article gives a systematic review of the literature regarding BTX in the treatment of major depression. METHODS: We screened the databases of Medline and Scopus using the search terms [("botulinum toxin" OR "botox") AND ("antidepressant" OR "depression" OR "depressed")]. The website www.clinicaltrials.gov was screened with the same search terms in order to detect current studies. RESULTS: As of April 2013, we identified 3 studies that evaluated the antidepressant effects of BTX in the treatment of major depression. An improvement in mood after treatment with BTX was seen in a case series of 10 depressed patients. In a randomised, placebo-controlled study of thirty patients assigned to a verum (BTX, n = 15) or placebo (saline, n = 15) group, treatment with BTX has also shown a positive effect on mood. Another prospective, open-label study evaluated the antidepressive effect of BTX in 25 subjects with major depression. On www.clinicaltrials.gov we identified 2 ongoing studies, which are currently investigating the antidepressant effect of BTX. CONCLUSION: Recently published studies have shown a reduction of depressive symptoms after treatment of the glabellar frown lines with BTX injections. Further clinical studies in larger patient samples are necessary to prove the efficacy and safety of BTX injections used for the treatment of depressive disorders. SN - 1439-3522 UR - https://www.unboundmedicine.com/medline/citation/24519192/[Botulinum_toxin_for_the_treatment_of_major_depressive_disorder]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0033-1356093 DB - PRIME DP - Unbound Medicine ER -